API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Digoxin tablets which is inhibiting Na-K ATPase, indicated for the treatment of mild to moderate heart failure in adults, increases myocardial contractility in pediatric patients with heart failure.
Lead Product(s): Digoxin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lanoxin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022